Atlas Trials

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Clinical trial NCT00394251 · COMPLETED

Trial details

NCT number
NCT00394251
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2006-08-01
Primary completion
2007-03-01
Enrollment
197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.